18 July 2023 : Original article
Recurrent Membranoproliferative Glomerulonephritis After Kidney Transplantation: Risk Factors and Impact on Graft Survival
Lais Ceccatto de Paula1ABCDEF, Marilda MazzaliDOI: 10.12659/AOT.940502
Ann Transplant 2023; 28:e940502
Table 2 Post-transplant characteristics of the kidney transplant recipients with native biopsy-proven membranoproliferative glomerulonephritis according to its recurrence after transplant.
| General | Non-MPGN recurrence | MPGN recurrence | p | |
|---|---|---|---|---|
| Age at transplant | 31.7±10.8 | 29.7±8.1 | 37.5±16.0 | 0.09## |
| Deceased donor, n (%) | 16 (57.1) | 13 (61.9) | 3 (42.9) | 0.42 |
| HLA A, B, DR mismatches | 3.1±1.8 | 3.5±1.7 | 2.0±1.9 | 0.06## |
| Cold ischemia time (hours) | 21.1±8.0 | 20.6±8.5 | 23.3±6.1 | 0.45## |
| Induction therapy, n (%) | ||||
| None | 19 (67.9) | 13 (61.9) | 6 (85.7) | 0.37# |
| Basiliximab | 3 (10.7) | 3 (14.3) | 0 (0.0) | |
| Thymoglobulin 3–6 mg/kg | 4 (14.3) | 3 (14.3) | 1 (14.3) | 1.00# |
| Other | 2 (7.1) | 2 (9.5) | 0 (0.0) | |
| Delayed graft function, n (%) | 9 (32.1) | 7 (33.3) | 2 (28.6) | 1.00# |
| Post-transplant follow-up | ||||
| Proteinuria, n (%) | 18 (64.2) | 11 (52.4) | 7 (100.0)* | |
| Edema, n (%) | 6 (21.4) | 2 (9.5) | 4 (57.1)* | 0.02# |
| Nephrotic syndrome, n (%) | 6 (21.4) | 2 (9.5) | 4 (57.1)* | 0.02# |
| Hematuria, n (%) | 15 (53.6) | 8 (38.1) | 7 (100.0)* | |
| C3 reduction | 7 (25.0) | 3 (14.3) | 4 (57.1)* | 0.04# |
| C4 reduction | 1 (3.6) | 0 (0.0) | 1 (14.3) | |
| Acute T cell-mediated rejection | 12 (42.9) | 7 (33.3) | 5 (71.4) | 0.10# |
| Acute antibody-mediated rejection | 2 (7.2) | 2 (9.5) | 0 (0.0) | |
| Histological features | ||||
| Crescents | 2 (7.2) | 0 (0.0) | 2 (28.6)* | |
| Mesangial hypercellularity | 8 (28.6) | 1 (4.8) | 7 (100.0)* | |
| Interstitial fibrosis | 12 (42.9) | 6 (28.6) | 6 (85.7)* | 0.02# |
| MPGN – membranoproliferative glomerulonephritis; HLA – human leukocyte antigen; * At MPGN recurrence; # Chi-square test; ## unpaired -test. | ||||






